Company selected for membership in highly competitive Bay Area biotech incubator

Silicon Valley, California, December 2025 | Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA complexes, today announced its acceptance into MBC BioLabs, one of the Bay Area’s leading incubators for early-stage life science companies. Gritstone has now been smoothly operating in its new lab space since October.

MBC BioLabs, with locations in San Francisco and San Carlos, is known for its highly competitive admission process and for enabling promising biotechnology companies to launch, scale, and accelerate their research through access to state-of-the-art laboratory infrastructure, capital equipment, and an active network of scientific, operational, and investor partners.

Through MBC BioLabs, Gritstone Bio has gained immediate access to fully equipped research laboratories, cutting-edge instrumentation, and expert operational support. This allows the company to focus resources on accelerating core scientific programs, including T cell–engaging modalities and peptide-centric cell therapies, while benefitting from the incubator’s vibrant community and partnerships with leading venture, pharmaceutical, and academic groups.

Since its founding, MBC BioLabs has become a central hub for biotech innovation in the Bay Area, providing turnkey laboratory space and fostering a community where early-stage companies can rapidly generate data, scale operations, and prepare for institutional investment.

Media Contact:
Rachel Miller
VP of Operations
Gritstone Bio
rmiller@gritstone.com

Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com